Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | HTR1D | P28221 | 4/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25204691 | 0.71 | CA2 (0.44) | HTR1ASIGMAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL30170372 | 0.71 | CA2 (0.44) | HTR1ASIGMAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL29462397 | 0.70 | CA2 (0.46) | HTR1ASIGMAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL4936360 | 0.68 | CA2 (0.56) | HTR1ASIGMAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL4936349 | 0.68 | CA2 (0.56) | HTR1ASIGMAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL6593801 | 0.67 | CA2 (0.44) | HTR1ASIGMAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL460126 | 0.67 | CA2 (0.44) | HTR1ASIGMAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL8638651 | 0.67 | CA2 (0.44) | HTR1ASIGMAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL155647 | 0.67 | CA2 (0.44) | HTR1ASIGMAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL3230349 | 0.67 | HTR1A (0.45) | HTR1ASIGMAR1ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602808-B | Method for synthesizing nebivolol intermediate | 曼纳里尼国际经营卢森堡有限公司 | 2021-11-02 | — | — | CN | disclosed |
| EP-3405467-B1 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES OF NEBIVOLOL | MENARINI INT OPERATIONS LUXEMBOURG SA (LU) | 2021-08-04 | — | — | EP | disclosed |
| US-10392361-B2 | Process for the synthesis of intermediates of Nebivolol | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2019-08-27 | — | — | US | disclosed |
| US-20190031636-A1 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES OF NEBIVOLOL | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2019-01-31 | — | — | US | disclosed |
| EP-3405467-A1 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES OF NEBIVOLOL | Menarini International Operations Luxembourg S.A. (LU) | 2018-11-28 | — | — | EP | disclosed |
| WO-2017125900-A1 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES OF NEBIVOLOL | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2017-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392361-B2 | Process for the synthesis of intermediates of Nebivolol | ADRB3, ADRB2, ADRB1 | HTR1A 694/4885SIGMAR1 685/4885ADRA2A 10/4885 |
| US-20190031636-A1 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES OF NEBIVOLOL | ADRB3, ADRB2, ADRB1 | HTR1A 694/4885SIGMAR1 685/4885ADRA2A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.